Insider
Pfizer IncPFE

Pfizer names Cecile Guegan chief financial officer

Pfizer Inc. has appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
the reflection of a building in the windows of another building
Photo by Sonia Dauer on Unsplash
$1,300,000
Annual base salary
$1,300,000
Target cash incentive

Key points

  • Pfizer’s board of directors unanimously elected Cecile Guegan as chief financial officer and executive vice president.
  • The appointment does not signal a change in corporate strategy or financial performance.

Appointment of permanent finance executive

Pfizer’s board of directors unanimously elected Cecile Guegan as chief financial officer and executive vice president. Guegan previously served as interim chief financial officer, effective August 16, 2026.

Guegan’s annual base salary is $1,300,000. She is also eligible for a target cash incentive of $1,300,000, which represents 100% of her annual salary. In this role, she oversees audit, treasury, investor relations, tax, and other corporate financial functions.

Annual compensation for the chief financial officer

Base salary
$1,300,000
Target incentive
$1,300,000
Data from the original sources listed alongside.

Significance of the appointment for shareholders

The appointment does not signal a change in corporate strategy or financial performance. This is a standard corporate decision to appoint a permanent executive following service on an interim basis.

Original sources

  1. 8-K filing, November 3, 2026November 3, 2026SHA-256 of our archived copy a5b33854d355…
  2. 8-K EX-99.1 filing, November 3, 2026November 3, 2026SHA-256 of our archived copy 1bcc52c47f96…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards